Main Content

Daniel Levy, MD

Hypertension 2022: Lessons from Observational Studies and Clinical Trials to Guide Patient Care
Friday, October 28, 2022
University of Mississippi Medical Center

Daniel Levy, M.D. is Director of the Framingham Heart Study, Chief of the Population Sciences Branch of the National Heart, Lung, and Blood Institute, and Professor of Medicine, Boston University School of Medicine. His main areas of research include epidemiology and applying multidimensional “omics” data to the study of hypertension, heart disease, and heart failure. As one of the founders of an international genetics consortium, he has led genome-wide association studies that have identified many of the known genes associated with hypertension. He leads the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) initiative, which seeks to integrate big data resources from thousands of Framingham Heart Study participants using genetic variation in their DNA, gene expression, microRNA expression, proteomics, metabolomics, and DNA methylation to identify casual genes, proteins, and pathways contributing to cardiovascular disease. Dr. Levy has twice received the National Institutes of Health Director’s Award for his research accomplishments. In November 2009 he was the recipient of the American Heart Association’s highest recognition for research achievements in epidemiology, the Population Research Prize. In recognition of his contributions to his field of research, the American Heart Association conferred the 2021 Excellence Award for Hypertension Research on Dr. Levy. Dr. Levy has published over 800 articles in leading medical journals. He was named by Thomson-Reuters/ClarivateAnalytics for seven consecutive years as one of the world’s most highly cited scientists based on his publication of multiple papers ranking in the top 1% by citations, considering both year and field of research. Dr. Levy authored an acclaimed book about the revolution in our understanding the causes of heart disease titled “A Change of Heart” (published by Alfred A. Knopf), and served as Editor-in-Chief of the Journal of the American Society of Hypertension. from 2014-2018 and currently serves as Editor-in-Chief of International Journal of Cardiology: Cardiovascular Risk and Prevention. He served on multiple U.S. guideline committees for hypertension and cholesterol treatment and has delivered keynote addresses at scores of national and international conferences.